---
title: Tai Chi for Patients With Essential Hypertension
nct_id: NCT04267471
overall_status: UNKNOWN
phase: NA
sponsor: Chengdu University of Traditional Chinese Medicine
study_type: INTERVENTIONAL
primary_condition: Hypertension
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04267471.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04267471"
ct_last_update_post_date: 2020-02-24
last_seen_at: "2026-05-12T07:21:33.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Tai Chi for Patients With Essential Hypertension

**Official Title:** Tai Chi for Patients With Essential Hypertension: Study Protocol of an Open-label Single-center Randomized Controlled Trial

**NCT ID:** [NCT04267471](https://clinicaltrials.gov/study/NCT04267471)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 234
- **Lead Sponsor:** Chengdu University of Traditional Chinese Medicine
- **Conditions:** Hypertension
- **Start Date:** 2020-06
- **Completion Date:** 2022-12
- **CT.gov Last Update:** 2020-02-24

## Brief Summary

Several studies investigating Tai Chi for hypertension have been carried out. However, investigators found the results were in high heterogeneity and poor methodological quality. Thus, investigators intend to provide high quality of the effectiveness and safety of Tai Chi for essential hypertension.

## Eligibility

- **Minimum age:** 45 Years
- **Maximum age:** 80 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. participants aged between 45 to 80 years;
2. participants diagnosed with mild to moderate hypertension, and meet the diagnostic criteria of mild to moderate hypertension according to 2018 Chinese guidelines for the management of hypertension (140≤SBP≤169 and/or 90≤DBP≤109);
3. participants with or without antihypertensive medication;
4. participants with no regular exercise in the past 3 months;
5. participants willing to comply with the study protocol;
6. participants willing to sign informed consent form.

Exclusion Criteria:

1. participants diagnosed with secondary hypertension or refractory hypertension;
2. participants with severe medical visceral condition and chronic diseases, such as diabetes, epilepsy, severe depression or anxiety, psychosis;
3. participants with severe bone and joint diseases or motor dysfunction limit ability to participant exercise;
4. participants with severe cognitive decline (Mini-Mental State Examination score, ≤ 20)
5. participants with weak muscle, poor balance or limited vision that would impede full participation in the study;
6. patients participate in other clinical trials at the same time.
```

## Arms

- **Tai Chi** (EXPERIMENTAL) — 3 sessions of Tai Chi per week for 12 weeks
- **Walking** (ACTIVE_COMPARATOR) — 3 sessions of walking per week for 12 weeks
- **Waiting-list** (NO_INTERVENTION)

## Interventions

- **Tai Chi** (BEHAVIORAL) — Tai Chi is a traditional Chinese mind-body exercise, which combines deep-breath relaxation and gentle movements in sequence with meditation. Each session of Tai Chi will last 60 minutes, including a 10-minute warm-up, a 40-minute Tai Chi practice and a 10-minute cool-down.
- **Walking** (BEHAVIORAL) — Each session of walking will last 60 minutes, including a 10-minute warm-up, a 40-minute walking and a 10-minutes cool-down.

## Primary Outcomes

- **average 24-h Systolic Blood Pressure (SBP)** _(time frame: change from baseline to 12 weeks after intervention)_

## Secondary Outcomes

- **average SBP and average Diastolic Blood Pressure (DBP)** _(time frame: baseline, after intervention(12 week), after follow-up(24 week))_
- **change of serum concentrations of Nitric Oxide** _(time frame: baseline, after intervention(12 week))_
- **change of serum concentrations of endothelin** _(time frame: baseline, after intervention(12 week))_
- **change of serum concentrations of thromboxane A2** _(time frame: baseline, after intervention(12 week))_
- **change of serum concentrations of vascular endothelial growth factor** _(time frame: baseline, after intervention(12 week))_
- **blood pressure measured at home with an upper arm electronic sphygmomanometer** _(time frame: baseline, after intervention(12 week), after follow-up(24 week))_
- **Medical Outcomes Study 36-Item Short Form** _(time frame: baseline, after intervention(12 week))_

## Locations (1)

- Affiliated Hospital of Chengdu University of Traditional Chinese Medicine (Sichuan Provincial Hospital of Traditional Chinese Medicine), Chengdu, Sichuan, China

## Recent Field Changes (last 30 days)

- `status.completionDate` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.affiliated hospital of chengdu university of traditional chinese medicine (sichuan provincial hospital of traditional chinese medicine)|chengdu|sichuan|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04267471.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04267471*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*